Ampio Pharmaceuticals, Inc. (AMPE)
| Market Cap | 5.90K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.63M |
| Shares Out | 1.14M |
| EPS (ttm) | -10.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 502 |
| Average Volume | 1,250 |
| Open | 0.0052 |
| Previous Close | n/a |
| Day's Range | 0.0052 - 0.0052 |
| 52-Week Range | 0.0001 - 0.2951 |
| Beta | 7.78 |
| RSI | 39.41 |
| Earnings Date | n/a |
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado. [Read more]
Financial Performance
Financial StatementsNews
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form ...
Ampio Announces Voluntary Delisting and SEC Deregistration
ENGLEWOOD, Colo. , March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily del...
Ampio Provides Update on Results from Pre-IND Enabling Studies
ENGLEWOOD, Colo. , Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a...
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions
ENGLEWOOD, Colo. , Jan. 11, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a...
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
ENGLEWOOD, Colo. , Oct. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential t...
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
ENGLEWOOD, Colo. , Oct. 5, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential tr...
Ampio Pharmaceuticals Announces Reverse Stock Split
ENGLEWOOD, Colo. , Aug. 31, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors has approved a 20-to-1 reverse stock spli...
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock
ENGLEWOOD, Colo. , May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth ...
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS
ENGLEWOOD, Colo. , April 18, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi a...
Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
ENGLEWOOD, Colo. , Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE A...
Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension
ENGLEWOOD, Colo. , Nov. 17, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the "Company") received notification from NYSE American LLC ("NYSE American" or the "Exchan...
Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split
Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), announced today that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implem...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuti...
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 17, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("...
Ampio Pharmaceuticals Issues Letter to Stockholders
Proposal to Authorize Reverse Stock Split has Been Approved ENGLEWOOD, Colo. , Oct. 14, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), today released the following le...
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuti...
MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceuti...
Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings
ENGLEWOOD, Colo. , Oct. 4, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") received written notification from NYSE American LLC ("NYSE American" or the "Exchange...
NYSE American to Suspend Trading Immediately in Ampio Pharmaceuticals, Inc. (AMPE) and Commence Delisting Proceedings
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ...
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ampio Pharmaceut...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ampio Pharmaceuti...
The Law Offices of Frank R. Cruz Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) on behalf of investors concern...
Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders
ENGLEWOOD, Colo. , June 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatmen...
Ampio's Independent Committee Launches Investigation Related To AP-013 Trial
Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of indep...
Ampio Pharmaceuticals Reports First-Quarter Financial Results
ENGLEWOOD, Colo. , May 16, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatmen...